Endocrine Abstracts

Introduction: PWS results from lack of expression of genes on the paternally inherited chromosome 15q11.2-q13. Clinical manifestations include hypotonia, altered body composition, reduced growth and a high incidence of obstructive sleep apnoea (OSA). Impaired GH secretion is documented in children with PWS. Recombinant growth hormone (rGH) use poses a therapeutic challenge due to potential life threatening adverse events, namely, the theoretical risk of increased lymphoid tiss...

Introduction: Mauriac first described a syndrome in 1930 of growth failure, delayed puberty and hepatomegaly in children with type 1 diabetes. This was in the era prior to long acting insulin analogues being available. With the now widespread availability of various insulin analogues and near patient testing to optimise glucose control, this syndrome was presumed to be of historical interest only. There are increasing reports in the literature of the resurgence of this once fo...

Introduction: NICE CG15 (2004) recommends that diabetic patients aged over twelve years receive seven key care processes. The National Paediatric Diabetes Audit (NPDA) aims to improve outcomes and quality of care in paediatric diabetes. The following describes what proportion of children with type 1 diabetes in our Paediatric Diabetes Unit (PDU) are receiving these seven key care processes in comparison to the NPDA (2013–14).Audit Methodology: Patie...

Introduction: NICE CG15 (2004) states that children with diabetes should receive care to achieve optimum control to reduce risk from diabetes complications. The National Paediatric Diabetes Audit (NPDA) aims to improve outcomes in paediatric diabetes. The following describes the outcomes of care in our Paediatric Diabetes Unit (PDU) in comparison to the NPDA (2013-14).Audit Methodology: Patients aged 1–17 years with a diagnosis of diabetes for &#880...